Identifying and characterizing COPD patients in US managed care. A retrospective, cross-sectional analysis of administrative claims data

Douglas W Mapel, Michael P Dutro, Jeno P Marton, Kimberly Woodruff, Barry Make, Douglas W Mapel, Michael P Dutro, Jeno P Marton, Kimberly Woodruff, Barry Make

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death among US adults and is projected to be the third by 2020. In anticipation of the increasing burden imposed on healthcare systems and payers by patients with COPD, a means of identifying COPD patients who incur higher healthcare utilization and costs is needed.

Methods: This retrospective, cross-sectional analysis of US managed care administrative claims data describes a practical way to identify COPD patients. We analyze 7.79 million members for potential inclusion in the COPD cohort, who were continuously eligible during a 1-year study period. A younger commercial population (7.7 million) is compared with an older Medicare population (0.115 million). We outline a novel approach to stratifying COPD patients using "complexity" of illness, based on occurrence of claims for given comorbid conditions. Additionally, a unique algorithm was developed to identify and stratify COPD exacerbations using claims data.

Results: A total of 42,565 commercial (median age 56 years; 51.4% female) and 8507 Medicare patients (median 75 years; 53.1% female) were identified as having COPD. Important differences were observed in comorbidities between the younger commercial versus the older Medicare population. Stratifying by complexity, 45.0%, 33.6%, and 21.4% of commercial patients and 36.6%, 35.8%, and 27.6% of older patients were low, moderate, and high, respectively. A higher proportion of patients with high complexity disease experienced multiple (≥2) exacerbations (61.7% commercial; 49.0% Medicare) than patients with moderate- (56.9%; 41.6%), or low-complexity disease (33.4%; 20.5%). Utilization of healthcare services also increased with an increase in complexity.

Conclusion: In patients with COPD identified from Medicare or commercial claims data, there is a relationship between complexity as determined by pulmonary and non-pulmonary comorbid conditions and the prevalence of exacerbations and utilization of healthcare services. Identification of COPD patients at highest risk of exacerbations using complexity stratification may facilitate improved disease management by targeting those most in need of treatment.

Figures

Figure 1
Figure 1
Stratification of patients in the study.
Figure 2
Figure 2
COPD Patients Registering an inpatient exacerbation or experiencing any exacerbation, stratified by complexity, for (A) commercial, and (B) Medicare cohorts. †Any exacerbation includes inpatient hospitalized exacerbation, an ambulatory exacerbation with qualifying diagnosis or ambulatory exacerbation with qualifying drug therapy.

References

    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. (Updated 2009) Accessed January 13, 2011.
    1. National Heart Lung and Blood Institute. Morbidity and Mortality. 2009 Chartbook on Cardiovascular, Lung, and Blood Diseases. Accessed January 13, 2011.
    1. World Health Organization. COPD predicted to be third leading cause of death in 2030. Accessed January 13, 2011.
    1. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543–1554. doi: 10.1056/NEJMoa0805800.
    1. Tashkin DP, Celli B, Decramer M, Liu D, Burkhart D, Cassino C, Kesten S. Bronchodilator responsiveness in patients with COPD. Eur Respir J. 2008;31:742–750. doi: 10.1183/09031936.00129607.
    1. Wilt TJ, Niewoehner D, MacDonald R, Kane RL. Management of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guideline. Ann Intern Med. 2007;147:639–653.
    1. Mapel DW, Hurley JS, Frost FJ, Petersen HV, Picchi MA, Coultas DB. Health care utilization in chronic obstructive pulmonary disease. A case-control study in a health maintenance organization. Arch Intern Med. 2000;160:2653–2658. doi: 10.1001/archinte.160.17.2653.
    1. Cydulka Rita K, McFadden ER Jr, Emerman Charles L, Sivinski Lynn D, Pisanelli W, Rimm Alfred A. Patterns of hospitalization in elderly patients with asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1997;156:1807–1812.
    1. Anecchino C, Rossi E, Fanizza C, De Rosa M, Tognoni G, Romero M. Prevalence of chronic obstructive pulmonary disease and pattern of comorbidities in a general population. Int J Chron Obstruct Pulmon Dis. 2007;2:567–574.
    1. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: Role of comorbidities. Eur Respir J. 2006;28:1245–1257. doi: 10.1183/09031936.00133805.
    1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997;349:1269–1276. doi: 10.1016/S0140-6736(96)07493-4.
    1. American Thoracic Society/European Respiratory Society Task Force. Standards for the Diagnosis and Management of Patients with COPD [Internet] New York: American Thoracic Society, Version 1.2; Accessed January 13, 2011.
    1. Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5:549–555. doi: 10.1513/pats.200709-148ET.
    1. McGhan R, Radcliff T, Fish R, Sutherland ER, Welsh C, Make B. Predictors of rehospitalization and death after a severe exacerbation of COPD. Chest. 2007;132:1748–1755. doi: 10.1378/chest.06-3018.
    1. Terzano C, Conti V, Di Stefano F, Petroianni A, Ceccarelli D, Graziani E, Mariotta S, Ricci A, Vitarelli A, Puglisi G, De Vito C, Villari P, Allegra L. Comorbidity, hospitalization, and mortality in COPD: Results from a longitudinal study. Lung. 2010;188:321–329. doi: 10.1007/s00408-009-9222-y.
    1. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789. doi: 10.1056/NEJMoa063070.
    1. Mannino DM, Doherty DE, Sonia Buist A. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med. 2006;100:115–122. doi: 10.1016/j.rmed.2005.03.035.
    1. Kim S, Clark S, Camargo CA Jr. Mortality after an emergency department visit for exacerbation of chronic obstructive pulmonary disease. COPD. 2006;3:75–81. doi: 10.1080/15412550600651271.
    1. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000;117:398S–401S. doi: 10.1378/chest.117.5_suppl_2.398S.
    1. Mannino DM, Davis KJ. Lung function decline and outcomes in an elderly population. Thorax. 2006;61:472–477. doi: 10.1136/thx.2005.052449.
    1. Kerstjens HA, Brand PL, Postma DS. Risk factors for accelerated decline among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;154:S266–272.
    1. Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. COPD. 2010;7:214–228. doi: 10.3109/15412555.2010.481697.
    1. Andersson F, Borg S, Jansson SA, Jonsson AC, Ericsson A, Prutz C, Ronmark E, Lundback B. The costs of exacerbations in chronic obstructive pulmonary disease (COPD) Respir Med. 2002;96:700–708. doi: 10.1053/rmed.2002.1334.
    1. Soriano JB, Davis KJ, Coleman B, Visick G, Mannino D, Pride NB. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest. 2003;124:474–481. doi: 10.1378/chest.124.2.474.

Source: PubMed

Подписаться